NYSE:NVTA - InVitae Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.24 -1.04 (-7.83 %)
(As of 11/14/2018 08:17 AM ET)
Previous Close$13.28
Today's Range$12.21 - $13.54
52-Week Range$4.35 - $18.38
Volume1.14 million shs
Average Volume1.18 million shs
Market Capitalization$990.92 million
P/E Ratio-4.62
Dividend YieldN/A
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medical laboratories
Current SymbolNYSE:NVTA
Previous Symbol


Debt-to-Equity Ratio0.29
Current Ratio3.90
Quick Ratio3.90


Trailing P/E Ratio-4.62
Forward P/E Ratio-6.15
P/E GrowthN/A

Sales & Book Value

Annual Sales$68.22 million
Price / Sales13.39
Cash FlowN/A
Price / CashN/A
Book Value$2.40 per share
Price / Book5.10


EPS (Most Recent Fiscal Year)($2.65)
Net Income$-123,380,000.00
Net Margins-109.60%
Return on Equity-103.37%
Return on Assets-59.39%


Outstanding Shares74,620,000
Market Cap$990.92 million

InVitae (NYSE:NVTA) Frequently Asked Questions

What is InVitae's stock symbol?

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

How were InVitae's earnings last quarter?

InVitae Corp (NYSE:NVTA) posted its quarterly earnings data on Wednesday, November, 7th. The medical research company reported ($0.45) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.47) by $0.02. The medical research company earned $37.37 million during the quarter, compared to analyst estimates of $34.80 million. InVitae had a negative net margin of 109.60% and a negative return on equity of 103.37%. The company's revenue for the quarter was up 105.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.57) EPS. View InVitae's Earnings History.

When is InVitae's next earnings date?

InVitae is scheduled to release their next quarterly earnings announcement on Monday, February 11th 2019. View Earnings Estimates for InVitae.

What price target have analysts set for NVTA?

5 brokers have issued 1-year price objectives for InVitae's shares. Their forecasts range from $10.00 to $16.00. On average, they expect InVitae's stock price to reach $12.75 in the next twelve months. This suggests a possible upside of 4.2% from the stock's current price. View Analyst Price Targets for InVitae.

What is the consensus analysts' recommendation for InVitae?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InVitae.

Has InVitae been receiving favorable news coverage?

News stories about NVTA stock have trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. InVitae earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the near term.

Who are some of InVitae's key competitors?

Who are InVitae's key executives?

InVitae's management team includes the folowing people:
  • Dr. Randal W. Scott, Exec. Chairman (Age 60)
  • Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 44)
  • Ms. Shelly D. Guyer, Chief Financial Officer (Age 58)
  • Mr. Lee Bendekgey, Chief Operating Officer (Age 60)
  • Ms. Patricia E. Dumond, Chief Accounting Officer & VP of Fin. (Age 53)

When did InVitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Who are InVitae's major shareholders?

InVitae's stock is owned by a variety of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (13.28%), BlackRock Inc. (7.29%), Gilder Gagnon Howe & Co. LLC (5.96%), Private Wealth Partners LLC (0.64%), Bank of New York Mellon Corp (0.43%) and Allianz Asset Management GmbH (0.36%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for InVitae.

Which major investors are selling InVitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd., Blair William & Co. IL, GSA Capital Partners LLP, Gamco Investors INC. ET AL and Teton Advisors Inc.. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Katherine Stueland, Patty Dumond, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Insider Buying and Selling for InVitae.

Which major investors are buying InVitae stock?

NVTA stock was acquired by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, ARK Investment Management LLC, Allianz Asset Management GmbH, Fuller & Thaler Asset Management Inc., BlackRock Inc., EAM Global Investors LLC, Private Wealth Partners LLC and Russell Investments Group Ltd.. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker, Geoffrey Crouse and Randal W Scott. View Insider Buying and Selling for InVitae.

How do I buy shares of InVitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is InVitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $12.24.

How big of a company is InVitae?

InVitae has a market capitalization of $990.92 million and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. InVitae employs 594 workers across the globe.

What is InVitae's official website?

The official website for InVitae is http://invitae.com.

How can I contact InVitae?

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]

MarketBeat Community Rating for InVitae (NYSE NVTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  530
MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel